Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer
May 19th 2020Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.
Chaft Crafts Considerations for Restarting Immunotherapy in Lung Cancer
May 19th 2020Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.
Sawyers Explains Lessons Learned After Atezolizumab/Enzalutamide Falls Short in mCRPC
May 8th 2020Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.
Pemigatinib Pivotal Cholangiocarcinoma Data Published as FDA Weighs Approval
April 16th 2020Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.